Articles tagged with Drug Resistance
A new study by Massachusetts General Hospital researchers highlights the risk of drug-resistant E. coli infections in patients receiving fecal microbiota transplants, particularly those who are immunocompromised. The study's findings emphasize the need for improved donor screening to prevent transmission of these resistant organisms.
A recent study uses whole-genome sequencing to understand the evolutionary history of an XDR-TB strain that emerged in KwaZulu-Natal, South Africa. The research identifies key factors contributing to its spread, including HIV coinfection and human migration, highlighting the importance of early detection and containment strategies.
A new antiviral drug blocks RNA polymerase, inducing mutations in the genetic material of the influenza virus and rendering it nonfunctional. The study found the drug to be highly efficacious against various strains of the flu, including seasonal and pandemic viruses.
Researchers have identified a new mechanism by which cancer cells become resistant to ferroptosis, a type of cell death. A molecule called FSP1 acts as a lipid antioxidant, rescuing cancer cells from ferroptosis even when they are starved of GPX4.
Scientists have developed a new class of drug that blocks the APOBEC3B enzyme in cancer cells, which is responsible for treatment resistance. This discovery has the potential to support existing cancer therapies and make treatments more effective by targeting cancer evolution.
Researchers found that differences at the single-cell level can predict responses to BRAF inhibitor therapy, and leveraging these differences may improve patient outcomes. Maintaining a population of cells within the drug-sensitive State 1 was critical to maintaining drug sensitivity.
A randomized controlled trial demonstrates Wirelessly Observed Therapy (WOT) superior to directly observed therapy (DOT) in boosting TB treatment adherence, with all patients cured and preferring WOT. The novel technology allows for private medication taking while preserving patient autonomy and enabling targeted treatment support.
Researchers used a new technique to identify genetic profiles of individual cells in a breast cancer tumor and found a drug combination that reversed resistance. The study suggests that clinicians could begin combination therapy before resistance occurs, given the effectiveness of the additional drug.
A study published in Annals of Neurology found that the spread of seizures through the brain can be suppressed by a
A team of scientists developed a technique using light to activate an Iridium-based compound that cuts off the 'power source' in cancer cells, even under hypoxia. This method could reduce side effects and potentially immunize against future cancers.
Researchers have designed a new class of modified pantothenamides that stop malaria parasites from replicating in humans and preventing transmission to mosquitoes. These compounds are effective against malaria parasites resistant to currently available drugs.
Biomedical engineers at Duke University developed a method to overcome limitations of gene-targeted cancer drugs by combining CRISPR/Cas9 targeting with sustained release drug delivery. This strategy effectively addressed potency, elimination, and resistance issues, demonstrating improved efficacy in mice with colorectal cancers.
A study of 284 patients found that those with more severe OSA had higher blood pressure, especially at night. The researchers suggest that clinicians should consider performing a sleep study in patients with resistant hypertension to treat OSA and lower blood pressure.
A systematic review and meta-analysis suggests that people with drug-resistant epilepsy have better prospects of being seizure-free if they undergo surgical treatment at an earlier stage. The study found a 15-21% higher probability of attack freedom for those who underwent surgery early compared to later stages.
Researchers at Trinity College Dublin have discovered new biological targets that may help combat cancers resistant to existing drugs. The study, published in Molecular Cell, reveals the importance of 'accessory components' in targeting Polycomb genes and their role in regulating cellular identity.
Researchers have identified a peptide from an Antarctic sponge that shows promise as a lead for new therapies against malaria. The compound, friomaramide, effectively blocked the development of the malaria parasite in liver cells without harming them.
A clinical study comparing liquid and tissue biopsies finds multiple resistance mechanisms in individual patients, which could explain why targeted therapies often fail. The results suggest possible molecular mechanisms underlying drug resistance, pointing the way to new and more personalized therapeutics.
Researchers at Cold Spring Harbor Laboratory have discovered a way to tackle the development of resistance in pancreatic cancer by targeting the ERBB signaling pathway. This approach has shown promise in shrinking pancreatic tumors in mice, providing a potential avenue for overcoming resistance and improving treatment outcomes.
A new report by The Lancet Commission on malaria eradication suggests that malaria can be eradicated by 2050 with the right tools, strategies, and sufficient funding. The report analyzes existing evidence with new epidemiological and financial analyses to demonstrate the feasibility of eradication.
Scientists investigated the genetic diversity of Plasmodium falciparum across sub-Saharan Africa, identifying distinct regional characteristics and potential drivers of variation. Human movement and malaria drug resistance are key factors contributing to this diversity, emphasizing the need for targeted interventions.
A Rutgers New Jersey Medical School study has found a genetically tractable cause of drug tolerant tuberculosis, paving the way for researchers to develop new drugs. The reversible mutations in the M.tuberculosis glpK gene produce a transient form of tolerance that disappears after treatment withdrawal.
Scientists have identified a cellular pathway that allows acute myeloid leukemia cells to evade the effects of drugs. They then engineered a compound that targets this pathway, blocking a mutant protein and halting the cancer cells' ability to sidestep the compound's effects.
Researchers discovered a three-drug combination that sensitizes cancer cells to treatment, overcoming cross-therapy resistance. The approach involves time-sensitive administration of glucose-6-phosphate dehydrogenase inhibitors alongside other drugs.
Researchers developed an elastic polymer with broad-spectrum antimicrobial properties, effectively killing viruses and drug-resistant bacteria. The polymer's unique molecular architecture attracts water to kill microbes within five minutes, making it a potential solution for hospital-acquired infections.
The ADVANCE study found that dolutegravir-containing regimens perform as well as the current efavirenz-containing one used for first-line antiretroviral treatment in South Africa, with minimal side effects and a greater resistance barrier. The new regimens are cheaper and may revolutionize ART in South Africa and beyond.
Scientists suggest that global warming may have enabled the emergence of Candida auris as a deadly human-infecting pathogen. The fungus can grow at higher temperatures than its relatives, hinting at recent adaptation.
Researchers have discovered the precise mechanism behind 5-Fluorouracil resistance in cancer, revealing a previously unknown protein called BOK as the key to understanding this phenomenon. Without BOK, cancer cells become dormant and can survive chemotherapy treatment before mutating into more aggressive forms.
A new study found that combining targeted drugs palbociclib and crizotinib is significantly more effective against cancer cells in the laboratory than either drug used alone. The combination approach may broaden the clinical use of palbociclib beyond breast cancer to include other tumour types.
Research reveals that epigenetic regulation-mediated metabolic reprogramming enables lung cancer cells to adapt to and resist targeted therapies. BCAT1 upregulation allows for glutathione generation, eliminating oxidative stress and promoting drug resistance.
Researchers found that immune cells were six times more active in tumours resistant to cetuximab. Immunotherapies designed to boost the immune system could be effective against these cancers. A phase II clinical trial has begun to test this approach.
A team of researchers has discovered a new way to target the unique metabolism of drug-resistant parasites, using a molecule called rhodoquinone. This approach could lead to the development of new drugs that selectively kill parasites without harming humans.
A Duke University study identifies over 100 human genes co-opted by malaria parasites during the silent earlier stages of infection. This finding could lead to new treatments and prevent the disease from spreading.
The University of Illinois Chicago is collaborating with TB Alliance to develop new clinical-stage drug candidates for treating tuberculosis, a bacterial infection resistant to available antibiotics. The five-year research project aims to produce two new treatments, with UIC receiving up to $9 million in funding.
Researchers at Oregon State University have discovered two compounds, deguelin and rotenone, that can inhibit the metabolism of melanoma cancer cells, effectively starving them of energy. This breakthrough offers a new potential treatment option for drug-resistant metastatic melanoma.
IDIBELL researchers have discovered a biomarker that predicts resistance to the chemotherapy drug docetaxel in triple-negative breast cancer. The study found that tumors with an amplified chromosome 12 region are more likely to develop resistance to docetaxel, but may be vulnerable to alternative treatment with carboplatin.
A new assay has been developed to detect patients' resistance to antimalarial drugs using whole blood, providing critical information quickly and efficiently in resource-limited settings. The technique eliminates DNA extraction steps, allowing for faster and more accurate assessment of genetic data associated with drug resistance.
Researchers identified a previously unknown pocket on the surface of picornaviruses, which can be stabilized by a newly-discovered compound. This stabilization prevents shape change and interaction with host cells, making it a promising strategy for developing antiviral medications.
Scientists have discovered a small molecule drug that can stop cancer cells from becoming resistant to chemotherapy. The compound, JH-RE-06, works by thwarting cancer's ability to survive and adapt to DNA damage caused by traditional chemotherapy drugs like cisplatin.
Susan Band Horwitz, an NFCR fellow, has been named a Giant of Cancer Care for her pioneering work on Taxol and its role in stabilizing microtubules to prevent cancer cell growth. Her research enabled the development of life-saving medications for ovarian, breast, and lung cancers.
Researchers at University of Malaga identify a fragment of the brain molecule Galanin as involved in anhedonia, a key symptom of depression. The study suggests potential new therapeutic strategies for treating depression and related addictions.
BCL-2 protein deregulation and transcriptional reprogramming contribute to Venetoclax resistance; researchers suggest targeting CDK7 as effective strategy to prevent resistance. Studies provide insights into drug resistance mechanism in B-cell lymphomas, paving way for potential co-treatment strategies.
Scientists at the Francis Crick Institute and Imperial College London have identified novel compounds that target a different part of the malaria parasite's enzyme, evading the same resistance mechanism. This study aimed to prevent malaria treatment resistance by studying how it evolves during drug development.
Researchers at MD Anderson Cancer Center discovered a small molecule drug, IACS-10759, that targets metabolic reprogramming and inhibits OXPHOS, leading to marked growth inhibition in ibrutinib-resistant mantle cell lymphoma cells. The study provides hope for patients with this incurable B-cell lymphoma.
Cancer cells' acquired resistance to anti-cancer drugs can be exploited as an Achilles heel, according to research that shows removing a MEK1/2 inhibitor drug causes reversal of drug resistance in colon cancer cell populations. This finding may inform decisions about intermittent use rather than continuous exposure.
Researchers at the University of Lincoln have successfully reproduced the complex 'anti-tumour antibiotic' kedarcidin, which shows promise in treating cancer and combating drug-resistant bacteria. The breakthrough could lead to new antibiotics and anticancer agents, offering hope for millions facing life-threatening infections.
A DNA rearrangement in immunoglobulin lambda (IgL) translocations is associated with poorer outcomes and reduced survival benefit from immunomodulatory drugs like lenalidomide. Patients with this genetic marker are more likely to relapse and die within the first three years after diagnosis.
A new study by researchers at the University of Illinois found that combining two cancer drugs, selinexor and 4-OHT, may prevent endocrine resistance in breast tumors. The treatment protocol was more effective than either drug alone in reducing tumor cells' viability.
Researchers have shed light on how leukemia cells become resistant to drugs and describe a potential solution using two drugs in combination. The study identifies the genes responsible for resistance, revealing that cancer cells overcome the lack of asparagine by breaking down proteins.
Moffitt researchers discovered that melanoma cells become resistant to BRAF inhibitors through a conserved stress response mechanism involving AP-1 activation and histone deacetylase 8. This finding suggests that HDAC inhibitors may be able to overcome resistance mechanisms, leading to potential new treatments.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
A collaborative research project has identified a previously uncharacterised genetic mutation in clinical isolates leading to resistance. The finding challenges current paradigms and paves the way for designing changes in therapy to overcome antifungal-resistant diseases.
Researchers develop drugs targeting specific component of folate pathway, potentially addressing drug resistance and treatment time. The compounds are more effective than existing antifolate medication PAS, offering hope for new treatment options.
A research collaboration between Columbia University and a genomicist has identified specific genetic pathways associated with antidepressant resistance. The team hopes to develop new treatments that can circumvent resistance in millions of people who do not respond to current medications.
Researchers at ISGlobal and ITM discovered that P. falciparum populations can develop resistance to certain antimalarial compounds by epigenetic changes in the expression of clag3 genes. This finding is significant because resistance acquired through epigenetic mechanisms can arise quickly, even during a single infection.
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
Scientists at Kanazawa University found that AXL protein is responsible for resistance to osimertinib, a tyrosine kinase inhibitor used to treat EGFR-mutated lung cancer. Inhibiting AXL expression can prevent tumor regrowth and improve treatment outcomes.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers develop a new assay to measure the eco-evolutionary interactions between sensitive and resistant tumor cells in non-small cell lung cancer. The study finds that by applying drug or eliminating fibroblasts, it is possible to 'treat the game', allowing for coopting of evolution to help patients